Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new consortium of 27 partners coordinated by the Nuffield Department of Clinical Neurosciences will tackle the challenge of discovery and characterisation of blood-brain barrier targets and transport mechanisms for brain delivery of therapeutics to treat neurodegenerative and metabolic diseases.

With this funding, we will be able to develop more sophisticated models that replicate the human blood-brain barrier far more accurately, allowing us to investigate how the barrier acts at a molecular level during disease.
- Zam Cader

The blood-brain barrier is a protective layer between the brain’s blood capillaries and the cells that make up brain tissue. This barrier provides a defence against the pathogens and toxins that may be in our blood, allowing very few molecules to pass through. It can also prevent many drugs from passing across into the brain, and this presents a major problem in treating neurological conditions and metabolic diseases, especially when using antibody therapies. On the other hand, several neurological diseases could originate from a dysfunctional blood-brain barrier.

The funding from the Innovative Medicines Initiative (IMI) to the IM2PACT consortium will allow this public-private partnership, which includes leading international experts in the field, to facilitate the development of drugs to treat neurological disorders by: 

  • discovering and developing innovative and effective brain transport mechanisms
  • establishing and characterising blood-brain barrier models with good predictability in health and disease
  • identifying translational read-outs closer to the pathogenesis of neurodegeneration and mimicking altered blood-brain barrier under disease conditions
  • in-depth understanding of the biology of the blood-brain barrier and characterisation of various pathophysiological mechanisms across the blood-brain barrier.

IM2PACT will foster the development of disease-modifying treatment in a setting of personalised medicine.

Dominique Lesuisse, Head of the Central Nervous System Barrier Group at Sanofi and IM2PACT project leader, said: 'Our existing models are not effective enough at telling us which drugs in particular biotherapeutics will break through the blood-brain barrier. IM2PACT will progress the state of the art and help devise optimal ways of getting therapies into the brain.'

With a budget of €18m, €9m of direct funding from IMI and €9m of in-kind funding from industry, IM2PACT is forming a large partnership to better understand the blood-brain barrier. The Innovative Medicines Initiative 2 Joint Undertaking is Europe’s biggest public private partnership and is funded jointly by the European Union´s Horizon 2020 research and innovation programme and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). 

 

Similar stories

How to use the science of the body clock to improve our sleep and health

Professor Russell Foster has written a new book about circadian neuroscience which is published by Penguin this week. This book review by Jacqueline Pumphrey was first published on the University of Oxford website.

NICE recommends offering app-based treatment for people with insomnia instead of sleeping pills

Hundreds of thousands of people suffering from insomnia who would usually be prescribed sleeping pills could be offered an app-based treatment programme instead, NICE has said.

New Study Shows Simvastatin Can Change the Way People Experience Certain Emotions

This new study examines the effects of simvastatin on emotional processing, reward learning, verbal memory, and inflammation.

Developmental dynamics of the neural crest–mesenchymal axis in creating the thymic microenvironment

A new paper from researchers at the Department of Paediatrics and the Nuffield Department of Clinical Neurosciences has shown that fibroblasts in the thymus, often considered simply as dull “structural” cells, are much more complex than previously thought.

Oxford researchers part of major UK initiative to understand chronic pain

Oxford pain researchers are playing a major role in a new multi-million pound research programme launched by a consortium of funders, including UKRI, Versus Arthritis, Eli Lilly and the Medical Research Foundation.